Purchase Zolpidem (Ambien) sleep aid pills online

How and where to order Ambien, Belbien, Stilnox (Zolpidem Tartrate) 10 mg tablets online:

Prices: from $2.51 per pill
Discount: 5% coupon: 5off_2021 (for Shop 2 only)
Forms: Zolpidem Tartrate 10 mg tablets or capsules
Quantity: 30-300 pills
Type: Zolpidem Sanval brand, Zolpidem from Europe brand, Belbien brand (worldwide and EU2EU delivery), Ambien generic, Stilnox generic
Payment: Visa, Mastercard, AmEx, Cryptocurrency
Delivery: Registered airmail, international delivery service
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Ambien (Zolpidem Tartrate), a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Dosage and administration:

  • Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily.
  • Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening.
  • Geriatric patients and patients with mild to moderate hepatic impairment: recommended dose is 5 mg for men and women.
  • Lower doses of CNS depressants may be necessary when taken concomitantly with Ambien.
  • The effect of zolpidem may be slowed if taken with or immediately after a meal.

    Dosage forms and strengths:

  • Ambien, Belbien, Stilnox (Zolpidem Tartrate) tablets 5 mg, 10 mg.


    Signs and symptoms:

    In postmarketing experience of overdose with zolpidem tartrate alone, or in combination with CNS-depressant agents, impairment of consciousness ranging from somnolence to coma, cardiovascular and/or respiratory compromise, and fatal outcomes have been reported.

    Recommended Treatment

    General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Zolpidem's sedative hypnotic effect was shown to be reduced by flumazenil and therefore may be useful; however, flumazenil administration may contribute to the appearance of neurological symptoms (convulsions). As in all cases of drug overdose, respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Hypotension and CNS depression should be monitored and treated by appropriate medical intervention. Sedating drugs should be withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis in the treatment of overdosage has not been determined, although hemodialysis studies in patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.

    As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.


  • Patients who have experienced complex sleep behaviors after taking Ambien.
  • Known hypersensitivity to zolpidem.

    Warnings and precautions:

  • CNS-depressant effects: impairs alertness and motor coordination including risk of morning impairment. Risk increases with dose and use with other CNS depressants and alcohol. Instruct patients on correct use.
  • Need to evaluate for comorbid diagnoses: reevaluate if insomnia persists after 7 to 10 days of use.
  • Severe anaphylactic/anaphylactoid reactions: angioedema and anaphylaxis have been reported. Do not rechallenge if such reactions occur.
  • Abnormal thinking and behavioral changes: changes including decreased inhibition, bizarre behavior, agitation, and depersonalization have been reported. Immediately evaluate any new onset behavioral changes.
  • Depression: worsening of depression or suicidal thinking may occur. Prescribe the least amount of tablets feasible to avoid intentional overdose.
  • Respiratory depression: consider this risk before prescribing in patients with compromisedrespiratory function.
  • Hepatic impairment: Avoid Ambien (Zolpidem Tartrate) tablets use in patients with severe hepatic impairment.
  • Withdrawal effects: symptoms may occur with rapid dose reduction or discontinuation.

    Adverse reactions, side effects:

    Most commonly observed adverse reactions of zolpidem tablets were:
    Short-term ( < 10 nights): drowsiness, dizziness, and diarrhea. Long-term (28-35 nights): dizziness and drugged feelings.

    To report suspected adverse reactions of Ambien (Zolpidem Tartrate) tablets, contact Sanofi pharmaceutical company or your local FDA.

    Drug interactions:

  • CNS depressants, including alcohol: possible adverse additive CNS-depressant effects.
  • Imipramine: decreased alertness observed.
  • Chlorpromazine: impaired alertness and psychomotor performance observed.
  • CYP3A4 inducers (rifampin or St. John's wort): combination use may decrease effect.
  • Ketoconazole: combination use may increase effect.

    Use in specific populations:

  • Pregnancy: may cause respiratory depression and sedation in neonates with exposure late in the third trimester.
  • Lactation: a lactating woman may pump and discard breast milk during treatment and for 23 hours after Zolpidem (Ambien, Belbien, Stilnox) administration.
  • Pediatric use: safety and effectiveness not established. Hallucinations (incidence rate 7%) and other psychiatric and/or nervous system adverse reactions were observed frequently in a study of pediatric patients with attention-deficit/hyperactivity disorder.

    Drug abuse and dependence:

    Zolpidem Tartrate is classified as a controlled substance by local laws in some countries (for example, Schedule IV in the United States and Canada).

  • Preclinical Testing Solutions
    Throughout the
    Product Innovation Cycle.